Clinical Trials Browser

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT07389239 2026-02-20

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Phase 1/2 Not yet recruiting

24 enrolled

Gynecologic

Ovarian Neoplasms

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

15 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05821686 2025-02-12

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Phase 1/2 Not yet recruiting

10 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06504875 2024-07-17

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Not yet recruiting

23 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05810792 2023-11-22

PANCEP-1

Phase 2 Not yet recruiting

50 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Clinical Trials

RIOT 4B

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

PANCEP-1